Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Bruno Bockorny

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-9162-1560; OpenAlex author ID A5068892140. Sources: ClinicalTrials.gov.

Their work

Papers
17 (first author 3, last author 2)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
108
Papers, trials and grants by year

2014: 1 paper · 2015: none · 2016: none · 2017: none · 2018: none · 2019: none · 2020: 2 papers · 2021: 1 paper · 2022: 2 papers · 2023: none · 2024: 3 papers, 1 trial · 2025: 6 papers · 2026: 2 papers

Papers 17

  1. Impact of prior conventional irinotecan use on nanoliposomal irinotecan efficacy in advanced pancreatic cancer: a meta-analysis. Last author DOI 10.1016/j.esmoop.2026.107774↗
  2. Biomarker Analysis from Patients with Metastatic PDAC Treated with TGFβ Antibody NIS793 plus Abraxane + Gemcitabine versus Abraxane + Gemcitabine Alone in a Ph… Co-author DOI 10.1158/1078-0432.ccr-26-0805↗
  3. Perspectives of the medical oncologist regarding adjuvant chemotherapy for pancreatic cancer: An international expert survey and case vignette study. Co-author DOI 10.1016/j.ejso.2024.109544↗
  4. Association between ABO blood groups and pancreatic cancer outcomes: A systematic review and meta-analysis. Last author DOI 10.1016/j.pan.2025.06.002↗
  5. A Phase III Randomized Trial of Integrated Genomics and Avatar Models for Personalized Treatment of Pancreatic Cancer: The AVATAR Trial. Co-author DOI 10.1158/1078-0432.ccr-23-4026↗
  6. TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreat… Co-author DOI 10.1200/jco-25-00872↗
  7. Open-Label, Phase II Trial of Extracellular Regulated Kinase Inhibition Alone and in Combination With Autophagy Inhibition in Patients With Metastatic Pancreat… Co-author DOI 10.1200/po-25-00332↗
  8. Sonic hedgehog inhibitor suppresses carcinoma associated fibroblasts to prime Gemcitabine/Nab-Paclitaxel and anti-CTLA4 immunotherapy as sequential first-line … First author DOI 10.64898/2025.12.14.25342225↗
  9. Exploiting pancreatic cancer metabolism: challenges and opportunities. First author DOI 10.1016/j.molmed.2024.03.008↗
  10. A large-scale proteomics resource of circulating extracellular vesicles for biomarker discovery in pancreatic cancer. Co-author DOI 10.7554/elife.87369↗
  11. A large-scale proteomics resource of circulating extracellular vesicles for biomarker discovery in pancreatic cancer Co-author DOI 10.7554/elife.87369.3↗
  12. Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-20-4116↗
  13. Facts and Hopes in Immunotherapy of Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-21-3452↗
  14. Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Tr… Co-author DOI 10.1158/1078-0432.ccr-21-0929↗
  15. BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. Co-author DOI 10.1038/s41591-020-0880-x↗
  16. Discovery of New Targets to Control Metastasis in Pancreatic Cancer by Single-cell Transcriptomics Analysis of Circulating Tumor Cells. Co-author DOI 10.1158/1535-7163.mct-19-1166↗
  17. Association between HBsAg positivity and pancreatic cancer: a meta-analysis. First author DOI 10.1007/s12029-014-9618-7↗

Trials 1

  1. AGEN1423 and Botensilimab w/ or w/o Chemo in PDAC Principal investigator NCT05632328↗

Closest collaborators

The 25 strongest of 108 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Manuel M. Hidalgo · 8 shared papers, 2020–2025 · strength 1.20
  2. Teresa Mercade Macarulla · 5 shared papers, 2020–2026 · strength 0.74
  3. Senthil K. Muthuswamy · 5 shared papers, 2020–2025 · strength 0.73
  4. Joseph Elan Grossman · 4 shared papers, 2022–2024 · strength 0.71
  5. Andrea J. Bullock · 4 shared papers, 2022–2025 · strength 0.60
  6. Mary Linton B. Peters · 3 shared papers, 2022–2026 · strength 0.58
  7. T.L. Correa · 2 shared papers, 2025–2026 · strength 0.55
  8. Ling Huang · 4 shared papers, 2020–2024 · strength 0.54
  9. Jaime Feliú · 4 shared papers, 2020–2025 · strength 0.53
  10. Leo L. Tsai · 3 shared papers, 2022–2024 · strength 0.45
  11. Mandeep Sawhney · 3 shared papers, 2022–2024 · strength 0.45
  12. Rocio García‐Carbonero · 2 shared papers, 2025 · strength 0.35
  13. Roberto Pazo-Cid · 2 shared papers, 2025 · strength 0.35
  14. Mariano Ponz‐Sarvisé · 3 shared papers, 2020–2025 · strength 0.34
  15. Steven D. Freedman · 2 shared papers, 2024 · strength 0.33
  16. Seohyuk Lee · 1 shared paper, 2026 · strength 0.32
  17. Carmen Guillén‐Ponce · 2 shared papers, 2021–2025 · strength 0.29
  18. Paola Cappello · 1 shared paper, 2024 · strength 0.28
  19. Maria Chiara De Santis · 1 shared paper, 2024 · strength 0.28
  20. Miriam Martini · 1 shared paper, 2024 · strength 0.28
  21. Brian Matthew Wolpin · 2 shared papers, 2020–2025 · strength 0.23
  22. Viviana Cremasco · 1 shared paper, 2026 · strength 0.20
  23. Marc R. Pelletier · 1 shared paper, 2026 · strength 0.20
  24. Mark Wong · 1 shared paper, 2026 · strength 0.20
  25. Li‐Yuan Bai · 1 shared paper, 2026 · strength 0.20

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.